Inicio>>Peptides>>Tat-ASIC1a (1-20) (mouse, rat) (trifluoroacetate salt)

Tat-ASIC1a (1-20) (mouse, rat) (trifluoroacetate salt) (Synonyms: NT1-20; Tat-Acid-sensing Ion Channel 1a (1-20))

Catalog No.GC91479

Tat-ASIC1a (1-20) es un péptido sintético compuesto por la secuencia de péptido que penetra en la célula del dominio de transducción de proteína Tat del VIH-1, unida a un péptido de 20 aminoácidos correspondiente a los aminoácidos 1-20 del canal iónico sensor ácido 1a (ASIC1a).

Products are for research use only. Not for human use. We do not sell to patients.

Tat-ASIC1a (1-20) (mouse, rat) (trifluoroacetate salt) Chemical Structure

Tamaño Precio Disponibilidad Cantidad
1mg
83,00 $
Disponible
5mg
330,00 $
Disponible
10mg
496,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Tat-ASIC1a (1-20) is a synthetic peptide composed of the cell-penetrating peptide sequence from the HIV-1 Tat protein transduction domain linked to a 20-amino acid peptide corresponding to amino acids 1-20 of acid-sensing ion channel 1a (ASIC1a).1 It prevents acid-induced association of ASIC1a with receptor-interacting serine/threonine kinase 1 (RIPK1) and necroptosis in primary mouse cortical neurons when used at a concentration of 10 µM. Tat-ASIC1a (1-20) decreases infarct volume in a mouse model of ischemia induced by middle cerebral artery occlusion (MCAO).

Reseñas

Review for Tat-ASIC1a (1-20) (mouse, rat) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tat-ASIC1a (1-20) (mouse, rat) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.